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Summary
Congenital lung anomalies are a group of rare malforma-
tions, often diagnosed during the prenatal period. Guide-
lines on how to manage these patients are currently under
debate, especially with regard to prophylactic surgery in
asymptomatic patients, or how to proceed with conserv-
ative follow-up. Currently, there is no clear consensus on
management strategies. A Swiss congenital lung anomaly
national database and biobank was created in 2016 to en-
able data recording and collection of surgical lung samples
in order to help define the most appropriate management
strategies. This national observational cohort study repre-
sents an important step towards a better understanding of
the pathophysiology and clinical course of the diseases in-
cluded under congenital lung anomalies, especially in the
context of a small country like Switzerland.
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Paediatric lung diseases
During recent decades, progress in innovative medical
technology, such as radiological or genetic investigations,
has helped to detect previously unnoticed asymptomatic
diseases. Paediatricians are increasingly faced with chil-
dren who have various types of pathology, including some
with a genetic signature or a prenatal diagnosis, but with-
out declared symptoms.
Currently, paediatric chronic lung diseases can arbitrarily
be classified in two groups (fig. 1). However, this list is in-
complete and does not consider all lung pathologies. For
instance, diseases with multifactorial causes, such as asth-
ma, are not included in this classification.
The first group includes lung diseases secondary to other
underlying illnesses, such as bronchiolitis obliterans
(caused by previous postnatal viral infections), bron-
chopulmonary dysplasia (caused by prematurity and early
neonatal insults), lung hypoplasia (as a consequence of
congenital renal disease or diaphragmatic hernia) and in-
terstitial lung diseases (secondary to glycogenosis or neu-
roendocrine cell hyperplasia of infancy). In this category,
paediatricians treat the initial symptoms in order to reduce
secondary pulmonary complications. For these patients,
there is a lack of genetic or clinical markers that could help
in adapting further management and follow-up.
The second group includes two different subgroups: first,
congenital lung diseases that are primary pathologies diag-
nosed in symptomatic or asymptomatic children. A genetic
cause is present in many of these diseases, such as cystic
Figure 1: Schematic classification of paediatric chronic lung
diseases. Italic text represents diseases where genetic mutations
have been reported, sometimes only for a subgroup of these lung
diseases.
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fibrosis, α1-antitrypsin deficiency, primary ciliary dyski-
nesia, several interstitial lung diseases, primary lung hy-
poplasia or primary pulmonary hypertension. If suspect-
ed, they can often be diagnosed through genetic analysis
or other specific investigations during the first year of life.
Their early identification enables paediatricians to be more
proactive in adjusting clinical follow-up.
Finally, congenital anatomical lung anomalies are a con-
tinuum of lung malformations that depend on factors such
as foregut, vascularisation, pulmonary parenchyma or air-
way components, and that are all related to abnormal em-
bryological development (fig. 2) [1]. In the spectrum of
these rare malformations, the most frequent are: congenital
pulmonary airway malformations (CPAMs) (previously
named congenital cystic adenomatoid malformations,
CCAM) (fig. 3A); bronchopulmonary sequestrations (fig
3B); and congenital lobar or segmental hyperinflation (pre-
viously named emphysema) (fig 3C) [2]. As a result of on-
going improvements in ultrasound technology, these mal-
formations are often diagnosed prenatally and 80% of them
are asymptomatic at birth [3]. The CPAM classification de-
scribed by Stocker includes five different types of focal le-
sion (0 to 4) [1], based on a macroscopic anatomical de-
scription of the lesion and a histological description of the
cells with haematoxylin and eosin staining after surgical
resection [4]. The CPAM types are differentiated by the
size of the cystic lesion and cell types present in the cys-
tic lesion (columnar, cuboidal or ciliated). However, this
phenotype description is not of much help in patient man-
agement, except for detecting a possible diagnosis of ma-
lignant transformation. From a research perspective, the
pathophysiological mechanisms leading to CPAM remain
unclear. Dysregulation of several genes that modify cell
proliferation and/or apoptosis has been suggested [5]. In-
terestingly, even if congenital lung diseases can often be
linked to genetic mutations, congenital lung anomalies of-
ten lack a known genetic footprint [6, 7]. In the majority,
Mendelian transmissions are not present and localised mal-
formations are most likely related to defects in cellular in-
teraction during lung formation [8].
Management of congenital lung anomalies
In Western Europe, the prevalence of congenital lung
anomalies is estimated to be 0.81 to 1.32/10,000 live births
(EUROCAT network 2010–2014). At birth, less than 20%
[9, 10] of new-borns with congenital lung anomalies have
symptoms, such as neonatal respiratory distress that could
require surgical intervention. The acute surgical interven-
tion usually consists of a pulmonary lobectomy, with re-
moval of an expansive and non-functional lung section.
The vast majority of new-borns do not present any respira-
tory symptoms [3]. In these cases, congenital lung anom-
alies can only be diagnosed by means of prenatal ultra-
sound screening. Undetected malformations may be
responsible for respiratory and/or vascular complications,
infections and, in rare cases, malignancy during later life
[11]. In asymptomatic children, postnatal computed to-
mography (CT) scans can help to confirm persistent ab-
normalities that are often subtle or not apparent on plain
radiographs. Until recently, the majority of multidiscipli-
nary medical teams managing asymptomatic children with
a confirmed diagnosis of congenital lung anomaly have
proposed prophylactic surgical intervention. The main ar-
gument backing surgical treatment is a decreased risk of
complications. In the literature, the risk of complications
associated with conservative disease management varies
from 20 to 60%, and they can occur any time between early
infancy and adulthood [12, 13]. In particular, data speak
in favour of prophylactic surgery in the first year of life,
since the complications of this are considered to be less
than those otherwise caused by the natural course of the
lung malformation.
Lately, the prophylactic surgical approach has been chal-
lenged. Several major medical centres and surgeon associ-
ations have suggested a nonoperative follow-up, reserving
surgery only for children who become symptomatic, de-
veloping complications, or have a known risk of addition-
al malignancy, such as patients with the DICER1 mutation
who have an increased risk of pleuropulmonary blastoma
[12, 14–17]. Unfortunately, the modalities of clinical fol-
low-up of patients with conservative treatment are not well
Figure 2: Spectrum of paediatric congenital lung anomalies.CPAM
= congenital pulmonary airways malformation; AVM = arteriove-
nous malformation
Figure 3: Thoracic computed tomography (CT) scans of paediatric patients with congenital lung anomalies. Coronal cuts of thoracic
CT scans performed between the ages of 4 and 6 months. Black arrows point at the lesion on each picture. A. Congenital pulmonary airway
malformation. B. Bronchopulmonary sequestration. C. Congenital lobar segmental emphysema.
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defined. They vary from radiological examinations (chest
X-ray and/or thoracic CT scan) only if clinical symptoms
are present [15], with a risk of diagnostic delay in ma-
lignancies, to regular radiological follow-up (thoracic CT
scan every 5 years, until at least 15 years of age) [17]. In
the second option, patients would be exposed to frequent,
maybe unnecessary, irradiation until adulthood. Interest-
ingly, reported complications are not more frequent during
the first years of life regardless of which clinical, nonoper-
ative follow-up is chosen [17].
These still unanswered questions as to which is the best
course of treatment to follow for congenital lung anomaly
patients led to the creation of a Swiss national database
and an associated biobank in 2016, with the aim of col-
lecting surgically resected abnormal lung specimens. This
project aims to promote collaboration between all the main
paediatric pulmonology centres and to acquire a clearer
overview of congenital lung anomalies in Switzerland.
The current status and role of national congen-
ital lung anomaly databases and cohorts
In Switzerland, several patient databases already exist. The
oldest one, focusing on cancer, was founded in 1970, and
has contributed to numerous scientific publications [18]
concerning adults as well as paediatric patients
(https://www.childhoodcancerregistry.ch). Its main goal is
to better understand malignant diseases, improve treat-
ments and avoid or minimise late side effects.
Treatment of rare diseases is often based on a poor level of
evidence because of the low prevalence of these patholo-
gies. Collaborative networks improve medical knowledge,
help to provide the best primary care while preserving pa-
tient safety, and lead to better documentation of outcomes
[19]. The availability of a platform accessible to all re-
searchers in a specific field and the promotion of data
sharing are fundamental [20]. A Swiss rare disease genet-
ic database already exists (SRDR) and collects data from
adults and children only in order to better characterise the
epidemiology of rare diseases in Switzerland. The goals of
the Swiss congenital lung anomaly database are to enable a
longitudinal follow-up of patients with direct improvement
in their long-term management.
Few national congenital lung anomaly patient cohorts exist
and they often have limited periods of observation [21]. In
France, several studies on congenital lung anomalies have
been performed using the French database created in 2008
(Respirare) and dedicated to rare pulmonary diseases. One
of these studies accurately reported the various complica-
tions at birth and the need for delivery to occur in a tertiary
care centre [3]. Another study performed on the French
database showed how prenatal ultrasound analyses of con-
genital pulmonary malformations made it possible to pre-
dict lung compression and evolution of the malformation
using the congenital lung volume ratio [22].
A study using an English congenital lung anomaly data-
base analysed the follow-up of 119 patients managed either
with prophylactic surgery or a conservative follow-up, be-
tween 1996 and 2009 [17]. Cook et al. suggested the pos-
sibility of avoiding surgery by frequent clinical and radio-
logical follow-ups until the age of 16 years. However, this
study did not take into account potential infectious risks
and malignant transformation beyond childhood.
A national Japanese congenital lung anomaly database pro-
vided data on postnatal evolution with and without prophy-
lactic surgery, including 428 patients diagnosed between
1992 and 2012 [23]. Kuroda et al. reported compensatory
lung growth in patients with malformation resection before
the age of 2 years, and normal vital capacity in subsequent
lung function tests. Their results also suggested the need to
follow up patients with an early lung resection, based on
the 10–15% risk of postoperative complications (such as
thoracic deformities or persistent lung cysts).
A large Chinese retrospective study on congenital lung
anomalies highlighted frequently incorrectly diagnosed
cases, and an increased risk of selection bias, such as
asymptomatic patients not being included in the study [24].
Thus, only a limited number of congenital lung anomaly
databases exist, and most of them are not shared, except for
the published results. Moreover, data are not collected in
a standardized way and are lacking in access for external
users [25]. Information on the number of patients included
in a register is rarely available and only a few websites,
such as Clinicaltrial.gov, provide such details.
A Swiss congenital lung anomaly database for
improved patient management
In Switzerland, approximately 35 new congenital lung
anomaly cases are diagnosed each year and are predomi-
nantly treated in the larger hospitals. Surgical resection re-
mains the preferred treatment in the majority of Swiss cen-
tres. However, the timing of surgery, and the clinical and
radiological follow up are not standardised.
Swiss paediatric experts believed that a national multicen-
tre database pooling all these patients could provide a com-
prehensive view of this small population, which would
help to reach consensus among the Swiss centres, despite
diverging clinical approaches and the number of medical
specialities involved in the management of these patients.
The opportunity to generate round table discussions and
the sharing of perspectives should result in improved ex-
pertise, as previously described by Chung [26]. There is al-
so the incentive to define more standardised management
guidelines through a participatory and cooperative con-
sensus. This challenging, multidisciplinary, multicentre ap-
proach is expected to bring real progress in the manage-
ment of congenital lung anomalies.
Briefly, in 2012 paediatric pulmonologists and surgeons of
the University Hospitals of Geneva initiated a prospective
database for this population. Nowadays congenital lung
malformations are mostly discovered prenatally, with post-
natal investigations and management. For this reason, the
prospective cohort study involves multiple specialists such
as obstetricians, neonatologists, radiologists, pulmonolo-
gists, paediatric surgeons and pathologists.
In 2016 and 2017, the project was extended to other Swiss
university hospitals (Basel, Bern, Lausanne, Zurich) and
large clinics offering the management of children with con-
genital lung anomalies (Lucerne; St Gallen). All patients
with a prenatal diagnosis are included in the database, no
matter which form of management was chosen (operative
or conservative). Informed consent is obtained from all the
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patients’ parents. Inclusion is planned to take place for at
least 10 more years, and if the first results are encouraging
the study could be extended for a longer period.
The Swiss congenital lung anomaly database contains the
following data (fig. 4): results of prenatal ultrasounds, sta-
tus at birth that includes information about respiratory sup-
port, clinical data obtained at each scheduled consultation,
radiological data, long-term respiratory follow-up with
lung function tests, and histological results if surgery is
performed.
All data are handled in collaboration with SwissPedNet,
the national paediatric research platform [27]. SwissPed-
Net supports data collection and management. In addition,
the SwissPedNet infrastructures are already available in all
participating centres.
In 2017, all participating centres were invited to share their
ideas and questions for scientific research related to this
national database. The aim of this brainstorming was to de-
fine projects that could be feasible for every participating
team, and to discuss authorship. In the case of publication,
it was agreed that authorship would depend on individual
contributions and the time spent on it, as described in re-
cent guidelines [28].
Among various research projects, two main topics were se-
lected:
1. Long-term follow-up of orthopaedic complications and
lung function. In the literature, orthopaedic complica-
tions including deformation of the thoracic wall and
scoliosis have been described in up to 35% of con-
genital lung anomaly cases, and usually occur during
growth [29, 30]. Rib fusion occurring after open
surgery is one of the possible causes of these complica-
tions. The aim is to establish the incidence such com-
plications in order to prevent them, bearing in mind
that nowadays minimally invasive surgery is per-
formed by paediatric surgeons rather more often than
open surgery. Only few data published on these pa-
tients have reported the presence of a restrictive dis-
ease affecting preoperative lung function [31], and res-
piratory function is normal in the majority of children
after lobectomy [32, 33]. However, no follow-up data
are available for these patients when they reach the
age of puberty. In addition, the question remains as to
whether non-functional pulmonary parenchyma could
be an obstacle to normal lung function. Comparing the
respiratory function test of operated versus non-operat-
ed children could help to determine the course of treat-
ment.
2. Comparison of preoperative thoracic CT scans and
magnetic resonance imaging (MRI). Currently, in most
centres congenital lung anomalies are investigated dur-
ing the first months of life by using classical radiolog-
ical examinations to accurately characterise the lesion
(localisation, size of the lesion, presence of cysts, ab-
normal pulmonary parenchyma, abnormal vascularisa-
tion). However, chest X-ray is often not sufficient to
detect small lesions. Most centres currently choose a
contrast-enhanced CT scan for characterisation of the
lesions. However, this comes with the risks associated
with radiation. Some teams have recently started to in-
vestigate these patients using thoracic MRI, which has
the advantage of using non-ionising radiation. MRI is
currently not clearly recognised to have the same pre-
cision as a CT scan, even if thoracic MRI is increas-
ingly being used for the follow-up of lung pathologies
(e.g., cystic fibrosis and tumours) [34].
The importance of a biobank to understand
rare diseases: challenges, benefits and new
perspectives in the understanding of pathogen-
esis
A biobank is a systematic collection of biological speci-
mens (blood, human tissue, DNA or proteins) and health
information from participants. Ethics committee agree-
ment and patient informed consent are required to create
biobank specimens and for data collection. Moreover, a
biobank should be sufficiently large to avoid the bias of
genetic variants and reduce the impact of phenotype vari-
ation. The creation of a biobank depends on the collection
of high-quality specimens, allowing long-term use of sam-
ples. Variables such as the date/time of the sampling, col-
lection methods and type of final storage constitute impor-
tant information to be recorded. Best practice guidelines to
standardise sample collection have already been published
[35].
Together with databases, biobanks are a key instrument
for increasing knowledge of rare diseases, especially when
they enable the pooling of -omic (genomic/proteomic/tran-
scriptomic) and clinical data. Nowadays, the availability of
Figure 4: Data recorded at different stages of a congenital lung anomaly patient’s follow-up during childhood.
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biomaterials is proving essential for the study of disease
aetiology and pathogenesis, paving the way to highly ef-
fective targeted therapies [20]. Researchers are currently
faced with the paradigm shift in the genomic era, where re-
search has become more data intensive, and huge amounts
of -omics data derived from biological samples are gener-
ated as a part of personalised medicine research [36].
Various types of biobanks, such as private biobanks set up
by the pharmaceutical industry or national biobanks prin-
cipally dedicated to specific diseases, already exist. Sam-
ple collection methods may vary, depending on the type
of biobank. Despite recent efforts made to develop vi-
able biobanks, sample pooling is often difficult to achieve,
with poor sample sharing between researchers. Protocols
of sample collection and storage often differ between cen-
tres, with little communication between teams. The cre-
ation of general protocols for sample conservation, as pro-
posed by Swissbiobank, may help to minimise collection
bias. Additionally, the large amount of paraffin-embedded
tissues stored in pathology departments could be a further
source of samples ready to share for analysis. -Omics re-
search on fixed tissue could deliver real progress and avoid
the difficulty in obtaining fresh tissue samples for research.
In Switzerland, a hospital biobank, the Lausanne Institu-
tional Biobank (BIL), was created in 2013 [37]. The goal
of the BIL is to facilitate translational and clinical re-
search for a variety of investigators locally and regionally.
Recently, a new project supported by the Swiss National
Foundation has enabled the creation of a web-based plat-
form dedicated to biobanks . This platform will help in cre-
ating biobanks by adhering to a harmonised process. All
five university hospitals have been actively involved in this
project since 2015, with one reference person per centre.
A Swiss congenital lung anomaly biobank for
sample storage after lung resection
Nowadays the vast majority of research relating to con-
genital lung anomalies is based either on animal models
mimicking CPAM or on data retrieved from small patient
cohorts. Several studies have principally focused on the
risk of malignant transformation in congenital lung anom-
alies. A first study compared the clinical evolution of ten
patients with pleuropneumoblastoma diagnosed on bron-
choalveolar sections of patients with a preoperative diag-
nosis of CPAM [38]. A second study analysed the risk of
bronchalveolar carcinoma transformation CPAM type 1 in
seven patients with use of molecular analyses [39]. Both
studies came up against the difficulty of completely reject-
ing the oncological risk of CPAM and reiterated the impor-
tant role of biobank analysis.
Along with the national database, a national congenital
lung anomaly biobank was created to store all samples
obtained from patients after lung resection. This biobank
stores abnormal pulmonary tissue, adjacent healthy
parenchyma and blood samples. Its purpose is to improve
knowledge of a lesion’s risk of malignant transformation
and to increase the understanding of congenital lung anom-
aly physiopathology. Geneva’s team performed a prelim-
inary study on different CPAM samples, analysing pro-
teomics data and immunohistochemistry. First results have
shown significant proteomic profile differences between
CPAM forms, suggesting that CPAM might originate at
different stages of lung development (unpublished data).
Future experiments will enable a deeper understanding of
cellular interactions and may also help in finding new bio-
markers influencing the long-term clinical management of
these patients.
Conclusion
Implementation of databases and biobanks is fundamental
to research into all rare congenital diseases, especially dur-
ing the paediatric period. Pooling data from patients with
a rare disease, such as congenital lung anomaly, in a long-
term observational cohort study represents an important
step to a better understanding of the natural clinical evolu-
tion of these patients. Switzerland is a small country where
all medical university centres and large cantonal hospitals
manage these patients, and it is of utmost importance to
create such a database and biobank, first to support re-
search, secondly to determine pertinent questions raised
during our daily medical management, and thirdly to har-
monise treatment strategies. The creation of a focus group
dedicated to congenital lung anomalies is also expected
to increase interactions between all paediatric centres in
Switzerland and improve the quality of treatment for these
patients.
A biobank is complementary to a database. This powerful
combination allows the medical teams to exploit data and
samples with new research questions. The Swiss congen-
ital lung anomalies database and biobank is an ambitious
project with long-term aspirations. It is expected that it will
enable Swiss teams to compare their results and share their
expertise with other European and international registers,
as well as build the necessary bridges for optimal follow-
up patients with congenital lung anomalies.
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